Per Näsman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Per Näsman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Monica Ortendahl
Royal Institute of Technology, Stockholm, Sweden
3 shared publications - Erik Lundström
Department of Medical Sciences, Neurology, Uppsala University, Uppsala University Hospital, Uppsala, Sweden
2 shared publications - Eva Isaksson
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Stockholm, Sweden
2 shared publications - Alf Uttermalm
Swedish Social Insurance Agency, Box 802, 721 22 Västerås, Sweden
1 shared publication - Ann-Charlotte Laska
Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden
1 shared publication - Ann-Sofie Rudberg
Department of Clinical Sciences, Danderyd Hospital Karolinska Institutet Stockholm Sweden
1 shared publication
Latest Publications
- Open Access
- 8 January 2018
- Published by Springer Nature in Trials
- Vol. 19 (1) , 14
Enhancing Recruitment Using Teleconference and Commitment Contract (ERUTECC): study protocol for a randomised, stepped-wedge cluster trial within the EFFECTS trial
Many randomised controlled trials (RCTs) fail to meet their recruitment goals in time. Trialists are advised to include study recruitment strategies within their trials. EFFECTS is a Swedish, academic-led RCT of fluoxetine for stroke recovery. The trial’s primary objective is to investigate whether 20 mg fluoxetine daily compared with placebo for 6 months after an acute stroke improves the patient’s functional outcome. The first patient was included on 20 October 2014 and, as of 31 August 2017, EFFECTS has included 810 of planned 1500 individuals. EFFECTS currently has 32 active centres. The primary objective of the ERUTECC (Enhancing Recruitment Using Teleconference and Commitment Contract) study is to investigate whether a structured teleconference re-visit with the study personnel at the centres, accompanied by a commitment contract, can enhance recruitment by 20% at 60 days post intervention, compared with 60 days pre-intervention, in an ongoing RCT. ERUTECC is a randomised, stepped-wedge cluster trial embedded in EFFECTS. The plan is to start ERUTECC with a running-in period of September 2017. The first intervention is due in October 2017, and the study will continue for 12 months. We are planning to intervene at all active centres in EFFECTS, except the five top recruiting centres (n = 27). The rationale for not intervening at the top recruiting centres is that we believe they have reached their full potential and the intervention would be too weak for them. The hypothesis of this study is that a structured teleconference re-visit with the study personnel at the centres, accompanied by a commitment contract, can enhance recruitment by 20% 60 days post intervention, compared to 60 days pre-intervention, in an ongoing RCT. EFFECTS is a large, pragmatic RCT of stroke in Sweden. Results from the embedded ERUTECC study could probably be generalised to high-income Western countries, and is relevant to trial management and could improve trial management in the future. It might also be useful in clinical settings outside the field of stroke. The ERUTECC study was registered in the Northern Ireland Hub for Trials Methodology Research Studies Within a Trial repository ( SWAT58 ) on 30 April 2017. ClinicalTrials.gov, ID: NCT02683213 . Retrospectively registered on 2 February 2016.
- 8 January 2018
- Published by Springer Nature in Trials
- Vol. 19 (1) , 14
Open AccessEnhancing Recruitment Using Teleconference and Commitment Contract (ERUTECC): study protocol for a randomised, stepped-wedge cluster trial within the EFFECTS trial
Many randomised controlled trials (RCTs) fail to meet their recruitment goals in time. Trialists are advised to include study recruitment strategies within their trials. EFFECTS is a Swedish, academic-led RCT of fluoxetine for stroke recovery. The trial’s primary objective is to investigate whether 20 mg fluoxetine daily compared with placebo for 6 months after an acute stroke improves the patient’s functional outcome. The first patient was included on 20 October 2014 and, as of 31 August 2017, EFFECTS has included 810 of planned 1500 individuals. EFFECTS currently has 32 active centres. The primary objective of the ERUTECC (Enhancing Recruitment Using Teleconference and Commitment Contract) study is to investigate whether a structured teleconference re-visit with the study personnel at the centres, accompanied by a commitment contract, can enhance recruitment by 20% at 60 days post intervention, compared with 60 days pre-intervention, in an ongoing RCT. ERUTECC is a randomised, stepped-wedge cluster trial embedded in EFFECTS. The plan is to start ERUTECC with a running-in period of September 2017. The first intervention is due in October 2017, and the study will continue for 12 months. We are planning to intervene at all active centres in EFFECTS, except the five top recruiting centres (n = 27). The rationale for not intervening at the top recruiting centres is that we believe they have reached their full potential and the intervention would be too weak for them. The hypothesis of this study is that a structured teleconference re-visit with the study personnel at the centres, accompanied by a commitment contract, can enhance recruitment by 20% 60 days post intervention, compared to 60 days pre-intervention, in an ongoing RCT. EFFECTS is a large, pragmatic RCT of stroke in Sweden. Results from the embedded ERUTECC study could probably be generalised to high-income Western countries, and is relevant to trial management and could improve trial management in the future. It might also be useful in clinical settings outside the field of stroke. The ERUTECC study was registered in the Northern Ireland Hub for Trials Methodology Research Studies Within a Trial repository ( SWAT58 ) on 30 April 2017. ClinicalTrials.gov, ID: NCT02683213 . Retrospectively registered on 2 February 2016.
- Open Access
- 28 December 2017
- Published by Springer Nature in Trials
- Vol. 18 (1) , 627
The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis
Background: Small trials have suggested that fluoxetine may improve neurological recovery from stroke. FOCUS, AFFINITY and EFFECTS are a family of investigator-led, multicentre, parallel group, randomised, placebo-controlled trials which aim to determine whether the routine administration of fluoxetine (20 mg daily) for six months after an acute stroke improves patients’ functional outcome. Methods/Design: The core protocol for the three trials has been published (Mead et al., Trials 20:369, 2015). The trials include patients aged 18 years and older with a clinical diagnosis of stroke and persisting focal neurological deficits at randomisation 2–15 days after stroke onset. Patients are randomised centrally via each trials’ web-based randomisation system using a common minimisation algorithm. Patients are allocated fluoxetine 20 mg once daily or matching placebo capsules for six months. The primary outcome measure is the modified Rankin scale (mRS) at six months. Secondary outcomes include: living circumstances; the Stroke Impact Scale; EuroQol (EQ5D-5 L); the vitality subscale of the 36-Item Short Form Health Survey (SF36); diagnosis of depression; adherence to medication; serious adverse events including death and recurrent stroke; and resource use at six and 12 months and the mRS at 12 months. Discussion: Minor variations have been tailored to the national setting in the UK (FOCUS), Australia, New Zealand and Vietnam (AFFINITY) and Sweden (EFFECTS). Each trial is run and funded independently and will report its own results. A prospectively planned individual patient data meta-analysis of all three trials will provide the most precise estimate of the overall effect and establish whether any effects differ between trials or subgroups. This statistical analysis plan describes the core analyses for all three trials and that for the individual patient data meta-analysis. Recruitment and follow-up in the FOCUS trial is expected to be completed by the end of 2018. AFFINITY and EFFECTS are likely to complete follow-up in 2020. Trial registration: FOCUS: ISRCTN, ISRCTN83290762. Registered on 23 May 2012. EudraCT, 2011-005616-29. Registered on 3 February 2012. AFFINITY: Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Registered on 22 July 2011. EFFECTS: ISRCTN, ISRCTN13020412. Registered on 19 December 2014. Clinicaltrials.gov, NCT02683213. Registered on 2 February 2016. EudraCT, 2011-006130-16. Registered on 8 August 2014.
- 28 December 2017
- Published by Springer Nature in Trials
- Vol. 18 (1) , 627
Open AccessThe FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis
Background: Small trials have suggested that fluoxetine may improve neurological recovery from stroke. FOCUS, AFFINITY and EFFECTS are a family of investigator-led, multicentre, parallel group, randomised, placebo-controlled trials which aim to determine whether the routine administration of fluoxetine (20 mg daily) for six months after an acute stroke improves patients’ functional outcome. Methods/Design: The core protocol for the three trials has been published (Mead et al., Trials 20:369, 2015). The trials include patients aged 18 years and older with a clinical diagnosis of stroke and persisting focal neurological deficits at randomisation 2–15 days after stroke onset. Patients are randomised centrally via each trials’ web-based randomisation system using a common minimisation algorithm. Patients are allocated fluoxetine 20 mg once daily or matching placebo capsules for six months. The primary outcome measure is the modified Rankin scale (mRS) at six months. Secondary outcomes include: living circumstances; the Stroke Impact Scale; EuroQol (EQ5D-5 L); the vitality subscale of the 36-Item Short Form Health Survey (SF36); diagnosis of depression; adherence to medication; serious adverse events including death and recurrent stroke; and resource use at six and 12 months and the mRS at 12 months. Discussion: Minor variations have been tailored to the national setting in the UK (FOCUS), Australia, New Zealand and Vietnam (AFFINITY) and Sweden (EFFECTS). Each trial is run and funded independently and will report its own results. A prospectively planned individual patient data meta-analysis of all three trials will provide the most precise estimate of the overall effect and establish whether any effects differ between trials or subgroups. This statistical analysis plan describes the core analyses for all three trials and that for the individual patient data meta-analysis. Recruitment and follow-up in the FOCUS trial is expected to be completed by the end of 2018. AFFINITY and EFFECTS are likely to complete follow-up in 2020. Trial registration: FOCUS: ISRCTN, ISRCTN83290762. Registered on 23 May 2012. EudraCT, 2011-005616-29. Registered on 3 February 2012. AFFINITY: Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Registered on 22 July 2011. EFFECTS: ISRCTN, ISRCTN13020412. Registered on 19 December 2014. Clinicaltrials.gov, NCT02683213. Registered on 2 February 2016. EudraCT, 2011-006130-16. Registered on 8 August 2014.
- Open Access
- 15 May 2009
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 6 (5) , 1665-1675
Estimated Time for Occurrence of Smoking-Related Consequences among Pregnant and Non-Pregnant Women
Objectives: To study time estimates by women smokers for when smoking-related consequences will occur given continuing or quitting smoking. The relationship of these estimates to pregnancy and intent to quit smoking was also investigated. Methods: Over a two-week period, eighty women, selected to constitute four subgroups formed by pregnant vs. non-pregnant and trying vs. not trying to quit smoking, rated times at which they would expect smoking-related consequences to occur given continuing or quitting smoking. Results: Somatic health consequences were estimated to occur later than consequences related to mood and social relations. All consequences were estimated to occur later given quitting smoking. Pregnancy had an effect on the estimated time that consequences would occur, with pregnant women estimating earlier occurrence of consequences related to mood and social relations than non-pregnant women did. Conclusion: Health messages should stress consequences for somatic health in quitting smoking, since outcomes later in time might have too low a value to exert a positive effect on decisions to quit smoking.
- 15 May 2009
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 6 (5) , 1665-1675
Open AccessEstimated Time for Occurrence of Smoking-Related Consequences among Pregnant and Non-Pregnant Women
Objectives: To study time estimates by women smokers for when smoking-related consequences will occur given continuing or quitting smoking. The relationship of these estimates to pregnancy and intent to quit smoking was also investigated. Methods: Over a two-week period, eighty women, selected to constitute four subgroups formed by pregnant vs. non-pregnant and trying vs. not trying to quit smoking, rated times at which they would expect smoking-related consequences to occur given continuing or quitting smoking. Results: Somatic health consequences were estimated to occur later than consequences related to mood and social relations. All consequences were estimated to occur later given quitting smoking. Pregnancy had an effect on the estimated time that consequences would occur, with pregnant women estimating earlier occurrence of consequences related to mood and social relations than non-pregnant women did. Conclusion: Health messages should stress consequences for somatic health in quitting smoking, since outcomes later in time might have too low a value to exert a positive effect on decisions to quit smoking.
- 1 January 2008
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 34 (2) , 225-233
Judgments of Risk for Consequences of Continuing or Quitting Smoking—A Study of Pregnant and Nonpregnant Women Intending and Not Intending to Quit
Objectives: To study perceived smoking-related consequences of continuing and of quitting smoking. Methods: Eighty women, with subgroups formed by pregnant/nonpregnant women and trying/not trying to quit smoking, performed judgments of the probability for consequences to occur given the conditions of continuing or quitting smoking. Results: For both the pregnant and nonpregnant women, the probability that consequences will occur was rated as less likely given the condition of quitting smoking. The condition of quitting had its greatest effect on the probability that somatic consequences would occur. Conclusion: Consequences of smoking for somatic health should be stressed in health promotion, especially to pregnant women.
- 1 January 2008
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 34 (2) , 225-233
Judgments of Risk for Consequences of Continuing or Quitting Smoking—A Study of Pregnant and Nonpregnant Women Intending and Not Intending to Quit
Objectives: To study perceived smoking-related consequences of continuing and of quitting smoking. Methods: Eighty women, with subgroups formed by pregnant/nonpregnant women and trying/not trying to quit smoking, performed judgments of the probability for consequences to occur given the conditions of continuing or quitting smoking. Results: For both the pregnant and nonpregnant women, the probability that consequences will occur was rated as less likely given the condition of quitting smoking. The condition of quitting had its greatest effect on the probability that somatic consequences would occur. Conclusion: Consequences of smoking for somatic health should be stressed in health promotion, especially to pregnant women.
- 6 May 2007
- Published by Wiley in The American Journal on Addictions
- Vol. 16 (3) , 238-243
Use of Coping Techniques as a Predictor of Lapse When Quitting Smoking among Pregnant and Non‐Pregnant Women
We examined the number of lapses among pregnant and non‐pregnant women when trying to quit smoking, number of coping techniques used, and the relationship between any lapse and usage of coping techniques. Forty women were followed over a two‐week period. On day 14, the women rated how often eleven different coping techniques were used. One‐fourth of the women lapsed every day. If non‐pregnant, the odds ratio was eight times higher compared to being pregnant for any lapse during the period. Being pregnant gives a higher success rate in attempts to quit smoking.
- 6 May 2007
- Published by Wiley in The American Journal on Addictions
- Vol. 16 (3) , 238-243
Use of Coping Techniques as a Predictor of Lapse When Quitting Smoking among Pregnant and Non‐Pregnant Women
We examined the number of lapses among pregnant and non‐pregnant women when trying to quit smoking, number of coping techniques used, and the relationship between any lapse and usage of coping techniques. Forty women were followed over a two‐week period. On day 14, the women rated how often eleven different coping techniques were used. One‐fourth of the women lapsed every day. If non‐pregnant, the odds ratio was eight times higher compared to being pregnant for any lapse during the period. Being pregnant gives a higher success rate in attempts to quit smoking.